News and Trends 20 Jun 2017 Swedish Biotech publishes Long-Term Data on a Dendritic Cell Therapy for Cancer Immunicum has reported new data on long-term follow-up of patients treated with ilixadencel, a unique dendritic cell therapy against cancer. Immunicum is a Swedish biotech developing a cell-based therapy against cancer. The company has just published in the Journal for Immunotherapy for Cancer detailed results from a Phase I/II trial evaluating its lead candidate ilixadencel. The cell […] June 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 20 Jun 2017 “We’re at a second revolution in cancer therapy” – Experts discuss the Future of Oncology at Refresh A panel of experts in immuno-oncology discussed the challenges and opportunities to develop therapies that can effectively fight cancer. “I think right now we’re at a second revolution in cancer therapy, which surprisingly is not necessarily driven by technology but perspective, and how we look at cancer,” said Masoud Tavazoie, CEO of Rgenix. His company, based in New York, […] June 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2017 Results are in for Europe’s First Biobanking Study on HPV Cervical Cancer The RAIDs consortium made its closing event last week. After 4.5 years of studies, it has managed to change our appreciation of HPV cervical cancer towards building intelligent targeted therapy designs. Every year in Europe, 16,000 women die from cervical cancer and another 34,000 are newly diagnosed, which makes it the second most frequent form […] June 14, 2017 - 5 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jun 2017 BioNTech Publishes First Data on mRNA-Encoded Cancer Antibodies BioNTech has reported a new technology that could overcome some of the most challenging issues of antibody production by encoding them into mRNA drugs. BioNTech, one of the most advanced companies in the mRNA therapeutics field, has reported preclinical data for a new class of mRNA drugs that instruct the body to create its own […] June 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jun 2017 Norwegian Biotech Hits €21M in Private Placement for its Immunotherapies Targovax has raised €21M (NOK200M) in a private placement, which the biotech will use to fund data read-outs from clinical trials and CMC development. Targovax, based in Oslo, is developing a number of immunotherapies for treatment-resistant tumors. The biotech’s pipeline is based on its two platforms, ONCOS, an oncolytic virus, which is being developed to treat melanoma, […] June 12, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2017 What Cancer Therapies did European Biotechs Showcase at ASCO 2017? Here are the most innovative therapies presented by European biotechs fighting cancer during the ASCO 2017 meeting in Chicago. European biotech was in the spotlight during this year’s edition of the American Society of Clinical Oncology (ASCO) meeting, with impressive results from some of the most novel approaches under development to fight multiple forms of cancer. From a […] June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2017 New Dutch Biotech Gets Funding to Find Genetic Off Switches Scenic Biotech is applying a technology to identify first-in-class therapeutic targets that has secured it €6.5M in Series A. Scenic Biotech, founded in Amsterdam just this year, has raised €6.5M to exploit the potential of a technology to discover new types of disease-related genes with applications in cancer and rare genetic diseases. The company, created in […] June 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 2 Jun 2017 This French Biotech Wants to Reinvent DC-based Immunotherapies This week we had the chance to visit both Grenoble and Liège, where the French-Belgian biotech hybrid PDC*line Pharma has its two headquarters. The company is progressing new types of immunotherapies based on dendritic cells (DCs). Mission: PDC*line Pharma emerged from an R&D program of the French Blood Bank (EFS, Etablissement Français du Sang), where […] June 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2017 Next-Gen Drug Conjugates Bank €46M in Series B with American Investors Bicycle Therapeutics has closed a massive fundraising round, raking in £40M (€46M) from American investors to launch clinical trials. Bicycle Therapeutics, the most recent company founded by the legendary academic-entrepreneur Greg Winter, is making a name for itself as a money magnet. Hot on the heels of a €1B deal with AstraZeneca last fall, the biotech […] June 1, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 Swiss Biotech raises €10M to Target Elusive Protein Interactions in Cancer Inthera Bioscience has raised €9.6M in Series A to complete preclinical phase of its lead cancer program and expand its pipeline. Inthera Bioscience, located in Zurich, has closed a €9.6M (CHF 10.5M) Series A round led by Merck Ventures and backed by Novo Seeds and BioMedical Ventures, as well as a private investor. Members of Novo Seeds and […] May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 German Biotech Enters the Clinic with Next-Generation Antibody for AML Synimmune has hit the clinic with a first-in-human study of its Fc-optimized antibody FlySyn to treat patients with acute myeloid leukemia (AML). The German biotech Synimmune is developing next-generation anti-cancer antibodies to treat rare blood cancers. Its lead asset, FlySyn, is an antibody directed against the human fms-like tyrosine kinase 3 (FLT3) for the treatment of patients with […] May 31, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2017 Swiss Researchers get to the Genetic Bottom of Kidney Cancer Researchers from the University of Zurich have established a new mouse model of kidney cancer that could further our understanding of this deadly disease. Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer and in roughly half of the patients with this disease the tumor develops metastasis and can’t be […] May 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email